Analysts expect CytomX Therapeutics, Inc. (NASDAQ:CTMX) to announce earnings per share of ($0.22) for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for CytomX Therapeutics’ earnings. The highest EPS estimate is $0.23 and the lowest is ($0.40). CytomX Therapeutics posted earnings per share of ($0.31) in the same quarter last year, which would suggest a positive year-over-year growth rate of 29%. The business is expected to issue its next quarterly earnings report on Wednesday, February 23rd.
On average, analysts expect that CytomX Therapeutics will report full-year earnings of ($1.16) per share for the current year, with EPS estimates ranging from ($1.46) to ($0.59). For the next year, analysts forecast that the business will post earnings of ($1.51) per share, with EPS estimates ranging from ($1.74) to ($1.01). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow CytomX Therapeutics.
CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Thursday, November 4th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.05). The firm had revenue of $17.59 million for the quarter, compared to analysts’ expectations of $18.53 million. CytomX Therapeutics had a negative net margin of 108.85% and a negative return on equity of 65.76%. During the same quarter in the prior year, the business earned ($0.32) EPS.
Hedge funds have recently modified their holdings of the stock. Point72 Asset Management L.P. raised its position in shares of CytomX Therapeutics by 0.9% in the 2nd quarter. Point72 Asset Management L.P. now owns 6,393,900 shares of the biotechnology company’s stock worth $40,473,000 after acquiring an additional 58,900 shares in the last quarter. Vanguard Group Inc. grew its stake in CytomX Therapeutics by 15.0% during the 2nd quarter. Vanguard Group Inc. now owns 5,358,085 shares of the biotechnology company’s stock worth $33,917,000 after buying an additional 697,287 shares during the last quarter. State Street Corp grew its stake in CytomX Therapeutics by 37.4% during the 2nd quarter. State Street Corp now owns 4,616,562 shares of the biotechnology company’s stock worth $29,223,000 after buying an additional 1,257,697 shares during the last quarter. Candriam Luxembourg S.C.A. grew its stake in CytomX Therapeutics by 42.0% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 3,305,940 shares of the biotechnology company’s stock worth $16,826,000 after buying an additional 977,587 shares during the last quarter. Finally, Victory Capital Management Inc. grew its stake in CytomX Therapeutics by 13.9% during the 3rd quarter. Victory Capital Management Inc. now owns 3,269,112 shares of the biotechnology company’s stock worth $16,639,000 after buying an additional 400,126 shares during the last quarter. 89.60% of the stock is owned by hedge funds and other institutional investors.
NASDAQ CTMX opened at $3.95 on Friday. The stock has a market capitalization of $257.73 million, a PE ratio of -3.24 and a beta of 0.59. The business has a 50 day simple moving average of $5.80 and a two-hundred day simple moving average of $5.58. CytomX Therapeutics has a 1-year low of $3.67 and a 1-year high of $10.05.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W.
Recommended Story: What does a neutral rating on stocks mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.